a new Novo Nordisk drug still pending its definitive, liraglutide approval, has achieved a greater decrease in glycosylated hemoglobin in type 2 diabetes compared to those patients treated with other drugs, according to the results of aStudy published in the digital edition of the magazine 'The Lancet'.
Liraglutida is a new human LPG-1 analogWith 0.79 percent in the ex-inatida group, agonist of the LPG-1 receptor derived from lizard saliva.
In addition, after analyzing 464 patients, the liraglutida was also significantly better than exenatted in decreased plasma plasma glucose in patients with type 2 diabetes.
Both treatments led to a weight reduction as an average of 3 kilograms during the 26 -week study.The nausea were the adverse event notified more frequently with both treatments, but the results of the study showed that there were less persistent nausea and less hypoglycemic events with liraglutida against exenatida.
As noted by the head of Endocrinology and director of the Center for Diabetes Care at the Faculty of Medicine of the University of North Carolina (United States), John Bus Bus, the clinical benefits provided by Liraglutida -since a greater decrease inGlucose to a weight loss, through better tolerance and improvement in the function of beta cells- represent "a clinically significant advance" in treatment for patients with type 2 diabetes.
On April 23, 2009, Novo Nordisk announced that the Pharmaceutical Specialties Committee for Human Use (CHMP) of the European Medication Agency (EMEA, according to its acronym in English) adopted a positive opinion, recommending the authorization of marketing of Liraglutidafor the treatment of type 2 diabetes in Europe.
